Seattle Genetics commences everolimus-SGN-75 combination phase Ib clinical trial for advanced RCC

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the initiation of a phase Ib clinical trial evaluating SGN-75 in combination with everolimus (Afinitor^®) for patients with advanced metastatic renal cell carcinoma (RCC). The trial is designed to assess the safety and antitumor activity of SGN-75 in combination with everolimus. Seattle Genetics is a leader in the field of antibody-drug conjugates (ADCs) and SGN-75 is an ADC targeted to CD70.

“ADCs have the potential to change the way many types of cancer are treated, and we are excited to evaluate our ADC product candidate, SGN-75, in this phase Ib trial for patients with CD70-expressing RCC”

"ADCs have the potential to change the way many types of cancer are treated, and we are excited to evaluate our ADC product candidate, SGN-75, in this phase Ib trial for patients with CD70-expressing RCC," said Jonathan Drachman , M.D., Senior Vice President, Research and Translational Medicine at Seattle Genetics. "We are encouraged by the preliminary single-agent activity and tolerability demonstrated by SGN-75 in RCC patients and by our preclinical data suggesting synergy between auristatin-containing ADCs and mTOR inhibitors, including everolimus. We look forward to investigating whether this combination can provide therapeutic benefit to patients who currently have limited treatment options."

The study is a phase Ib, open-label, dose-escalation clinical trial to evaluate the safety and antitumor activity of SGN-75 in combination with everolimus, an mTOR inhibitor, in patients with CD70-positive metastatic RCC. Everolimus is an oral prescription medication used to treat advanced RCC when certain other medicines, such as sunitinib or sorafenib, have not worked. The trial is enrolling patients who have previously been treated with one or two tyrosine kinase inhibitors (TKIs). The primary endpoint of the trial is safety, with key secondary endpoints of best clinical response, progression-free survival (PFS) and overall survival (OS). The study is expected to enroll up to 40 patients at multiple centers in the United States.

"Despite the use of immunotherapy, tyrosine kinase inhibitors and mTOR inhibitors, many patients with kidney cancer ultimately experience progression of their disease," said Elisabeth Heath, M.D., Associate Professor of Oncology at Barbara Ann Karmanos Cancer Institute and investigator for this phase Ib clinical trial. "Kidney cancer tends to resist treatments after it stops responding to initial therapy, clearly demonstrating a need to identify new treatment approaches, such as targeted therapies directed to novel targets and combination therapy."